Stop Oxy Abuse Act of 2011

the Prescription Drug Abuse Prevention and Treatment Act of 2011 (S. 507/H.R. 1925) the Stop Oxy Abuse Act of 2011 (H.R. 1316) the Ryan Creedon Act of 2011 (H.R. 2119) Prescription Drug User Fee Act (PDUFA) reauthorization legislation (H.R. 5651/S. 3187)

Client expense: $30,430 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Office of Natl Drug Control Policy (NDCP), SENATE

Controlled Drug Substances Act (21 USC 13) Stop Oxy Abuse Act (H.R. 1316) Stop Tampering of Prescription Pills Act of 2012 (H.R. 6160)

Client expense: Not reported · Firm income: $15,750

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The Prescription Drug Marketing Act and issues relating to anti-counterfeiting/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse; H.R. 1316, Stop Oxy Abuse Act; H.R. 1065, Pill Mill Crackdown Act; Patient Protection and Affordable Care Act; H.R. 1483, Drug Safety Enhancement Act; Drug shortages; Preserving Access to Life-Saving Medications Act (S. 296); H.R.2245,Preserving Access to Life-Saving Medications Act of 2011

Client expense: $380,000 · Firm income: Not reported

Government targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE

H.R.1150 Competitive Health Insurance Reform Act of 2011 H.R.605 / S. 312 Patients' Freedom to Choose Act Medicare Physician Payment Reform H.R. 2863- Medicare Oral Health Rehabilitative Enhancement Act of 2011 H.R. 969 Medical Practice Freedom Act of 2011 S. 296 The Preserving Access to Life-Saving Medications Act H.R. 157 Health Care Safety Net enhancement Act of 2011 H.R. 1700/ S. 1042 Medicare Patient Empowerment Act H.R. 1316 Stop Oxy Abuse Act of 2011 S. 507 Prescription Drug Abuse Prevention and Treatment Act of 2011 H.R. 2104 Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act

Client expense: Not reported · Firm income: $30,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

the Prescription Drug Abuse Prevention and Treatment Act of 2011 (S. 507/H.R. 1925) the Stop Oxy Abuse Act of 2011 (H.R. 1316) the Ryan Creedon Act of 2011 (H.R. 2119) Prescription Drug User Fee Act (PDUFA) reauthorization legislation (H.R. 5651/S. 3187)

Client expense: $24,599 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE

Controlled Drug Substances Act (21 USC 13) Stop Oxy Abuse Act (H.R. 1316)

Client expense: Not reported · Firm income: $15,750

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The Prescription Drug Marketing Act and issues relating to anti-counterfeiting/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse; H.R. 1316, Stop Oxy Abuse Act; H.R. 1065, Pill Mill Crackdown Act; Patient Protection and Affordable Care Act; H.R. 1483, Drug Safety Enhancement Act; Drug shortages; Preserving Access to Life-Saving Medications Act (S. 296); H.R.2245,Preserving Access to Life-Saving Medications Act of 2011

Client expense: $510,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The Prescription Drug Marketing Act and issues relating to anti-counterfeiting/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse; H.R. 1316, Stop Oxy Abuse Act; H.R. 1065, Pill Mill Crackdown Act; Patient Protection and Affordable Care Act; H.R. 1483, Drug Safety Enhancement Act; Drug shortages; Preserving Access to Life-Saving Medications Act (S. 296); H.R.2245,Preserving Access to Life-Saving Medications Act of 2011

Client expense: $470,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1150- Competitive Health Insurance Reform Act of 2011 H.R. 605/ S. 312- Patients' Freedom to Choose Act Medicare Physician Payment Reform H.R. 2863- Medicare Oral Health Rehabilitative Enhancement Act of 2011 H.R. 969 Medical Practice Freedom Act of 2011 S. 296 The Preserving Access to Life-Saving Medications Act H.R. 157 Health Care Safety Net enhancement Act of 2011 H.R. 1700/ S. 1042 Medicare Patient Empowerment Act H.R. 1316 Stop Oxy Abuse Act of 2011 S. 507 Prescription Drug Abuse Prevention and Treatment Act of 2011 H.R. 2104 Consistency, Accuracy, Responsibilit, and Excellence in Medical Imaging and Radiation Therapy Act

Client expense: Not reported · Firm income: $30,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Drug shortages - Proposed legislation re these issues. Opiate abuse - HR 1316, Stop Oxy Abuse Act of 2011; HR 2119, Ryan Creedon Act of 2011; HR 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011; HR 1065, Pill Mill Crackdown Act of 2011; S 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; Executive Branch action re this issue. Pharmaceutical issues, including tracking and tracing medicines, fostering competition between generic and brand-name pharmaceutical manufacturers - HR 5651, Food and Drug Administration Reform Act of 2012; S 3187, Food and Drug Administration Safety and Innovation Act. Incentives to develop antibiotics - HR 2182, Generating Antibiotic Incentives Now Act of 2011; S 1734, Generating Antibiotic Incentives Now Act of 2011. Establish criminal penalties for trafficking in counterfeit drugs - HR 3468, Counterfeit Drug Penalty Enhancement Act of 2011; S 1886, Counterfeit Drug Penalty Enhancement Act of 2011. National Center for Advancing Transformational Sciences at FDA; agreement to review compounds for potential new uses - Executive Branch actions re these issues. *Follow-on biologics generally. *Certified Importer Program. *Drug safety - HR 1483, Drug Safety Enhancement Act of 2011.

Client expense: Not reported · Firm income: $100,000

Controlled Drug Substances Act (21 USC 13) Stop Oxy Abuse Act (H.R. 1316)

Client expense: Not reported · Firm income: $32,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

the Prescription Drug Abuse Prevention and Treatment Act of 2011 (S. 507/H.R. 1925) the Stop Oxy Abuse Act of 2011 (H.R. 1316) the Ryan Creedon Act of 2011 (H.R. 2119) Prescription Drug User Fee Act (PDUFA) reauthorization legislation (H.R. 5651/S. 3187)

Client expense: $117,767 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE

The Prescription Drug Marketing Act and issues relating to anti-counterfeiting/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse; H.R. 1316, Stop Oxy Abuse Act; H.R. 1065, Pill Mill Crackdown Act; Patient Protection and Affordable Care Act; H.R. 1483, Drug Safety Enhancement Act; Drug shortages; Preserving Access to Life-Saving Medications Act (S. 296); H.R.2245,Preserving Access to Life-Saving Medications Act of 2011

Client expense: $490,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1150- Competitive Health Insurance Reform Act of 2011 H.R. 605/ S. 312- Patients' Freedom to Choose Act Medicare Physician Payment Reform H.R. 969 Medical Practice Freedom Act of 2011 S. 296 The Preserving Access to Life-Saving Medications Act H.R. 157 Health Care Safety Net enhancement Act of 2011 H.R. 1700/ S. 1042 Medicare Patient Empowerment Act H.R. 1316 Stop Oxy Abuse Act of 2011 S. 507 Prescription Drug Abuse Prevention and Treatment Act of 2011 H.R. 2104 Consistency, Accuracy, Responsibilit, and Excellence in Medical Imaging and Radiation Therapy Act H.R. 2863- Medicare Oral Health Rehabilitative Enhancement Act of 2011

Client expense: Not reported · Firm income: $30,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

the Prescription Drug Abuse Prevention and Treatment Act of 2011 (S. 507/H.R. 1925) the Stop Oxy Abuse Act of 2011 (H.R. 1316) the Ryan Creedon Act of 2011 (H.R. 2119) Prescription Drug User Fee Act (PDUFA) reauthorization legislation

Client expense: $27,325 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE

Controlled Drug Substances Act (21 USC 13) Stop Oxy Abuse Act (H.R. 1316)

Client expense: Not reported · Firm income: $32,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

H.R. 1150- Competitive Health Insurance Reform Act of 2011; H.R. 605/ S. 312- Patients's Freedom to Choose Act; Medicare Physician Payment Reform; H.R. 2863- Medicare Oral Health Rehabilitative Enhancement Act of 2011; H.R. 969 Medical Practice Freedom Act of 2011 S. 296 The Preserving Access to Life-Saving Medications Act H.R. 157 Health Care Safety Net enhancement Act of 2011 H.R. 1700/ S. 1042 Medicare Patient Empowerment Act H.R. 1316 Stop Oxy Abuse Act of 2011 S. 507 Prescription Drug Abuse Prevention and Treatment Act of 2011 H.R. 2104 Consistency, Accuracy, Responsibilit, and Excellence in Medical Imaging and Radiation Therapy Act

Client expense: Not reported · Firm income: $20,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUM H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

The Prescription Drug Marketing Act and issues relating to anti-counterfeiting/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse; H.R. 1316, Stop Oxy Abuse Act; H.R. 1065, Pill Mill Crackdown Act; Patient Protection and Affordable Care Act; H.R. 1483, Drug Safety Enhancement Act; Drug shortages; Preserving Access to Life-Saving Medications Act (S. 296); H.R.2245,Preserving Access to Life-Saving Medications Act of 2011

Client expense: $520,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

the Prescription Drug Abuse Prevention and Treatment Act of 2011 (S. 507) the Stop Oxy Abuse Act of 2011 (H.R. 1316) the Ryan Creedon Act of 2011 (H.R. 2119)

Client expense: $28,611 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE

Controlled Drug Substances Act (21 USC 13) Stop Oxy Abuse Act (H.R. 1316)

Client expense: Not reported · Firm income: $45,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

S. 668, Health Care Bureaucrats Elimination Act. S. 1173, Ambulatory Surgical Center Quality and Access Act of 2011. H.R. 2108, Ambulatory Surgical Center Quality and Access Act of 2011. S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. H.R. 3070, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011. H.R. 1065, Pill Mill Crackdown Act of 2011. H.R. 1316, Stop Oxy Abuse Act of 2011. Monitor implementation of the Patient Protection and Affordable Care Act (P.L. 111-148). Monitor appropriations process and federal and legislative activity related to health care and reauthorization of National All Schedules Prescription Electronic Reporting Act (NASPER), (P.L. 109-60).

Client expense: Not reported · Firm income: $60,000

S. 668, Health Care Bureaucrats Elimination Act. S. 1173, Ambulatory Surgical Center Quality and Access Act of 2011. H.R. 2108, Ambulatory Surgical Center Quality and Access Act of 2011. S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. H.R. 3070, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011. H.R. 1065, Pill Mill Crackdown Act of 2011. H.R. 1316, Stop Oxy Abuse Act of 2011. Monitor implementation of the Patient Protection and Affordable Care Act (P.L. 111-148). Monitor appropriations process and federal and legislative activity related to health care and reauthorization of National All Schedules Prescription Electronic Reporting Act (NASPER), (P.L. 109-60).

Client expense: Not reported · Firm income: $60,000

S. 668, Health Care Bureaucrats Elimination Act. S. 1173, Ambulatory Surgical Center Quality and Access Act of 2011. H.R. 2108, Ambulatory Surgical Center Quality and Access Act of 2011. S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. H.R. 3070, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011. H.R. 1065, Pill Mill Crackdown Act of 2011. H.R. 1316, Stop Oxy Abuse Act of 2011. Monitor implementation of the Patient Protection and Affordable Care Act (P.L. 111-148). Monitor appropriations process and federal and legislative activity related to health care and reauthorization of National All Schedules Prescription Electronic Reporting Act (NASPER), (P.L. 109-60).

Client expense: Not reported · Firm income: $60,000

S. 668, Health Care Bureaucrats Elimination Act. S. 1173, Ambulatory Surgical Center Quality and Access Act of 2011. H.R. 2108, Ambulatory Surgical Center Quality and Access Act of 2011. S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. H.R. 3070, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011. H.R. 1065, Pill Mill Crackdown Act of 2011. H.R. 1316, Stop Oxy Abuse Act of 2011. Monitor implementation of the Patient Protection and Affordable Care Act (P.L. 111-148). Monitor appropriations process and federal and legislative activity related to health care and reauthorization of National All Schedules Prescription Electronic Reporting Act (NASPER), (P.L. 109-60).

Client expense: Not reported · Firm income: $60,000

The Prescription Drug Marketing Act and issues relating to anti-counterfeiting/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse; H.R. 1316, Stop Oxy Abuse Act; H.R. 1065, Pill Mill Crackdown Act; Patient Protection and Affordable Care Act; H.R. 1483, Drug Safety Enhancement Act; Drug shortages; Preserving Access to Life-Saving Medications Act (S. 296); H.R.2245,Preserving Access to Life-Saving Medications Act of 2011

Client expense: $490,000 · Firm income: Not reported

Government targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE

Prescription Drug Abuse; The Stop Oxy Abuse Act (H.R. 1316)

Client expense: $530,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1150 Competitive Health Insurance Reform Act of 2011 H.R. 605/ S. 312 Patients's Freedom to Choose Act Medicare Physician Payment Reform H.R. 2863 Medicare Oral Health Rehabilitative Enhancement Act of 2011 S. 507 Prescription Drug Abuse Prevention and Treatment Act of 2011 H.R. 1316 Stop Oxy Abuse Act of 2011 H.R. 1700/ S. 1042 Medicare Patient Empowerment Act H.R. 157 Health Care Safety Net Enhancement Act of 2011 S. 296 The Preserving Access to Life-Saving Medications Act H.R. 969 Medical Practice Freedom Act of 2011

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

the Prescription Drug Abuse Prevention and Treatment Act of 2011 (S. 507) the Stop Oxy Abuse Act of 2011 (H.R. 1316) the Ryan Creedon Act of 2011 (H.R. 2119)

Client expense: $18,836 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE

Controlled Drug Substances Act (21 USC 13) Stop Oxy Abuse Act (H.R. 1316)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."

S. 668, Health Care Bureaucrats Elimination Act. S. 1173, Ambulatory Surgical Center Quality and Access Act of 2011. H.R. 2108, Ambulatory Surgical Center Quality and Access Act of 2011. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011. H.R. 1065, Pill Mill Crackdown Act of 2011. H.R. 1316, Stop Oxy Abuse Act of 2011. Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. Monitor the implementation of the Patient Protection and Affordable Care Act (P.L. 111-148). Monitor appropriations process and federal and legislative activity related to health care and reauthorization of National All Schedules Prescription Electronic Reporting Act (NASPER), (P.L. 109-60).

Client expense: Not reported · Firm income: $100,000

S. 668, Health Care Bureaucrats Elimination Act. S. 1173, Ambulatory Surgical Center Quality and Access Act of 2011. H.R. 2108, Ambulatory Surgical Center Quality and Access Act of 2011. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011. H.R. 1065, Pill Mill Crackdown Act of 2011. H.R. 1316, Stop Oxy Abuse Act of 2011. Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. Monitor the implementation of the Patient Protection and Affordable Care Act (P.L. 111-148). Monitor appropriations process and federal and legislative activity related to health care and reauthorization of National All Schedules Prescription Electronic Reporting Act (NASPER), (P.L. 109-60).

Client expense: Not reported · Firm income: $100,000

S. 668, Health Care Bureaucrats Elimination Act. S. 1173, Ambulatory Surgical Center Quality and Access Act of 2011. H.R. 2108, Ambulatory Surgical Center Quality and Access Act of 2011. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011. H.R. 1065, Pill Mill Crackdown Act of 2011. H.R. 1316, Stop Oxy Abuse Act of 2011. Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. Monitor the implementation of the Patient Protection and Affordable Care Act (P.L. 111-148). Monitor appropriations process and federal and legislative activity related to health care and reauthorization of National All Schedules Prescription Electronic Reporting Act (NASPER), (P.L. 109-60).

Client expense: Not reported · Firm income: $100,000

S. 668, Health Care Bureaucrats Elimination Act. S. 1173, Ambulatory Surgical Center Quality and Access Act of 2011. H.R. 2108, Ambulatory Surgical Center Quality and Access Act of 2011. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011. H.R. 1065, Pill Mill Crackdown Act of 2011. H.R. 1316, Stop Oxy Abuse Act of 2011. Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. Monitor the implementation of the Patient Protection and Affordable Care Act (P.L. 111-148). Monitor appropriations process and federal and legislative activity related to health care and reauthorization of National All Schedules Prescription Electronic Reporting Act (NASPER), (P.L. 109-60).

Client expense: Not reported · Firm income: $100,000

The Prescription Drug Marketing Act and issues relating to anti-counterfeiting/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse; H.R. 1316, Stop Oxy Abuse Act; H.R. 1065, Pill Mill Crackdown Act; Patient Protection and Affordable Care Act; H.R. 1483, Drug Safety Enhancement Act; Drug shortages; Preserving Access to Life-Saving Medications Act (S. 296); H.R.2245,Preserving Access to Life-Saving Medications Act of 2011

Client expense: $560,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Prescription Drug Abuse; The Stop Oxy Abuse Act (H.R. 1316)

Client expense: $446,936 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1150 Competitive Health Insurance Reform Act of 2011 H.R. 605/S. 312 Patients' Freedom to Choose Act Medicare Physician Payment Reform Medicare Patent Physical Therapy Referral H.R. 969 Medical Practice Freedom Act of 2011 S. 296 the Preserving Access to Life-Saving Medications Act H.R. 157 Health Care Safety Net Enhancement Act of 2011 H.R. 1700/ S. 1042 Medicare Patient Empowerment Act H.R. 1316 Stop Oxy Abuse Act of 2011 S. 507 Prescription Drug Abuse Prevention and Treatment Act of 2011

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Controlled Drug Substances Act (21 USC 13) Stop Oxy Abuse Act (H.R. 1316)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

the Prescription Drug Abuse Prevention and Treatment Act of 2011 (S. 507) the Stop Oxy Abuse Act of 2011 (H.R. 1316) the Ryan Creedon Act of 2011 (H.R. 2119)

Client expense: $105,753 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 979, the FEHBP Prescription Integrity, Transparency and Cost Savings Act of 2011, legislation to reform the oversight authority for OPM for FEHBP drug benefit; H.R. 891 and S. 274, Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, Fairness in Medicare Bidding Act , this legislation would repeal the competitive bidding program in the Medicare Part B durable medical equipment prosthetics, orthotics and supplies (DMEPOS) program; worked with House and Senate Members on Congressional letter to CMS regarding the pending rule which was to be published on the new short cycle requirements for long-term care prescription dispensing; continue to work with Senate Committee on Aging on potential legislation addressing the role of nurses as agents in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study they are conducting on the 340B drug program which was mandated by Congress; FY12 National Defense Authorization Act, includes funding for for the TRICARE pharmacy program (bill not yet introduced); H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions relating to pedigree and track and trace-no bill introduced in the current Congress; H.R. 5234, the PBM Audit Reform ad Transparency Act of 2010 (111th Congress), no bill introduced in this Congress; H.R. 5235, Medicare Access to Diabetes Supplies Act (111th Congress), no bill introduced in this Congress; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national pharmacy benefit manager (PBM); submitted comments to House Energy and Commerce Committee for a hearing on the impact of health care reform on providers; submitted comments to House Committee on Oversight and Government Reform regarding the impact of certain regulations on small business pharmacies; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids From Dangerous Drugs Act of 2011.

Prescrition Drug User Fees; The Prescription Drug Marketing Act and issues relating to anti-counterfeiting/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse; H.R. 1316, Stop Oxy Abuse Act; H.R. 1065, Pill Mill Crackdown Act; Patient Protection and Affordable Care Act; H.R. 1483, Drug Safety Enhancement Act; Drug shortages; Preserving Access to Life-Saving Medications Act (S. 296);

Client expense: $650,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE